Company intelligence / Profile preview

ImmunoVec

Santa Monica, California, United Statesimmunovec.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

ImmunoVec is developing gene therapy treatments for life-threatening hematopoietic diseases. They have a platform for engineered lentiviral vectors that can modify patients' blood stem cells to introduce functional copies of genes. Their MyeloVec program for Chronic Granulomatous Disease is in preclinical stage, while their Wiskott-Aldrich Syndrome therapy is in discovery stage.

Therapeutic areas: ImmunologyHematology
Modalities: Gene therapyGene editing
Industry: Biotech

Beyond the preview

Go deeper on ImmunoVec.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImmunoVec.

Explore the full profile